Review of the Reported Measures of Clinical Validity and Clinical Utility as Arguments for the Implementation of Pharmacogenetic Testing: A Case Study of Statin-Induced Muscle Toxicity
Advances from pharmacogenetics (PGx) have not been implemented into health care to the expected extent. One gap that will be addressed in this study is a lack of reporting on clinical validity and clinical utility of PGx-tests. A systematic review of current reporting in scientific literature was co...
Saved in:
Main Authors: | Marleen E. Jansen (Author), T. Rigter (Author), W. Rodenburg (Author), T. M. C. Fleur (Author), E. J. F. Houwink (Author), M. Weda (Author), Martina C. Cornel (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2017-08-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Policy Guidance for Direct-to-Consumer Genetic Testing Services: Framework Development Study
by: Suzanne Maria Onstwedder, et al.
Published: (2024) -
Expanded Neonatal Bloodspot Screening Programmes: An Evaluation Framework to Discuss New Conditions With Stakeholders
by: Marleen E. Jansen, et al.
Published: (2021) -
DPD Testing Before Treatment With Fluoropyrimidines in the Amsterdam UMCs: An Evaluation of Current Pharmacogenetic Practice
by: Forike K. Martens, et al.
Published: (2020) -
The Pharmacogenetics of Statin Therapy on Clinical Events: No Evidence that Genetic Variation Affects Statin Response on Myocardial Infarction
by: Stella Trompet, et al.
Published: (2022) -
Pharmacogenetic educational needs and the role of pharmacogenetics in primary care: a focus group study with multiple perspectives
by: Maaike E. Ferwerda, et al.
Published: (2024)